Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 13/20 | 0.92 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | GUSB | P08236 | 1/20 | 0.61 |
| ▸ | CFTR | P13569 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14987166 | 0.96 | GLS (1.00) | GLSALDH1A1SMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL14987148 | 0.86 | GLS (1.00) | GLSALDH1A1SMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL22623553 | 0.84 | GLS (0.77) | GLSALDH1A1SMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL15724916 | 0.82 | GLS (0.80) | GLSALDH1A1SMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL15727673 | 0.82 | GLS (0.92) | GLSCYP2C9CYP2C19GUSBCFTR | |
| SCHEMBL21443368 | 0.82 | GLS (0.88) | GLS | |
| SCHEMBL14987445 | 0.82 | GLS (1.00) | GLS | |
| SCHEMBL15748887 | 0.82 | GLS (0.90) | GLSCYP2C9CYP2C19GUSBCFTR | |
| SCHEMBL14987559 | 0.81 | GLS (1.00) | GLSSMN1; SMN2 | |
| SCHEMBL16306827 | 0.80 | GLS (1.00) | GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2922832-B1 | GLUTAMINASE INHIBITORS AND METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2019-10-09 | — | — | EP | disclosed |